Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Gynoclin V

Phase 3Small molecule

Johnson & Johnson

Gynoclin V is one of 9 small molecule programs targeting Vaginitis. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

8

Competitors

Pipeline

Status by Indication[3][1]

Indication

VaginitisActive, not recruiting

VaginitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Vaginitis

#DrugCompanyPhaseTrials

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lotrimin

Chronulac

SSolvay Pharmaceuticals

Trolamine (biafine)

WWest China Hospital

Canesten

AAVVA Pharmaceuticals Ltd.

POLYGYNAX

LLaboratoire Innotech International

Gynoclin V

Johnson & Johnson

Albaconazole

TOL-463

TToltec Pharmaceuticals, LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vaginitis1 trial

A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01867164·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gynoclin V. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gynoclin V compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gynoclin V. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Related News